
In the early ‘90s, when pharmaceutical advances in pain and inflammation were taking shape for the first time in a decade, I was working on the identity of a blockbuster Cox-II inhibitor. The company had hired a major marketing firm to conduct research and develop strategy. It cost the client […] keep reading